Orphan designation: Azithromycin dihydrate Prevention of bronchopulmonary dysplasia, 14/01/2022 Positive
Retrieved on:
Tuesday, April 9, 2024
Community, Diagnosis, Civil service commission, Bronchopulmonary dysplasia, Ureaplasma urealyticum infection, BPD, Prevalence, Protein, Disease, Infection, Clinical, Inflammation, Patient, Committee, Bacteria, EMA, IRIS, Update, Agency, European, COMP, European Commission, Marketing, Medicine, Pharmaceutical industry
Overview
Key Points:
- Overview
This medicine was designated as an orphan medicine for the prevention of bronchopulmonary dysplasia in the European Union on 14 January 2022. - All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
- The full list of orphan designations is available in the Community register of orphan medicinal products for human use.
- EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: